Your browser doesn't support javascript.
loading
Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3.
Mocci, Evelina; Kundu, Prosenjit; Wheeler, William; Arslan, Alan A; Beane-Freeman, Laura E; Bracci, Paige M; Brennan, Paul; Canzian, Federico; Du, Mengmeng; Gallinger, Steven; Giles, Graham G; Goodman, Phyllis J; Kooperberg, Charles; Le Marchand, Loic; Neale, Rachel E; Shu, Xiao-Ou; Visvanathan, Kala; White, Emily; Zheng, Wei; Albanes, Demetrius; Andreotti, Gabriella; Babic, Ana; Bamlet, William R; Berndt, Sonja I; Blackford, Amanda L; Bueno-de-Mesquita, Bas; Buring, Julie E; Campa, Daniele; Chanock, Stephen J; Childs, Erica J; Duell, Eric J; Fuchs, Charles S; Gaziano, J Michael; Giovannucci, Edward L; Goggins, Michael G; Hartge, Patricia; Hassan, Manal M; Holly, Elizabeth A; Hoover, Robert N; Hung, Rayjean J; Kurtz, Robert C; Lee, I-Min; Malats, Núria; Milne, Roger L; Ng, Kimmie; Oberg, Ann L; Panico, Salvatore; Peters, Ulrike; Porta, Miquel; Rabe, Kari G.
Affiliation
  • Mocci E; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Kundu P; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Wheeler W; Information Management Services, Inc., Silver Spring, Maryland.
  • Arslan AA; Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York.
  • Beane-Freeman LE; Department of Population Health, New York University School of Medicine, New York, New York.
  • Bracci PM; Department of Environmental Medicine, New York University School of Medicine, New York, New York.
  • Brennan P; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Canzian F; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
  • Du M; International Agency for Research on Cancer, Lyon, France.
  • Gallinger S; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Giles GG; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Goodman PJ; Lunenfeld-Tanenbaum Research Institute, Sinai Health System and University of Toronto, Toronto, Ontario, Canada.
  • Kooperberg C; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Le Marchand L; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
  • Neale RE; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
  • Shu XO; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Visvanathan K; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • White E; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Zheng W; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Albanes D; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Andreotti G; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Babic A; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Bamlet WR; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Berndt SI; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Blackford AL; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Bueno-de-Mesquita B; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Buring JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Campa D; Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Chanock SJ; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Childs EJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Duell EJ; Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Fuchs CS; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands.
  • Gaziano JM; Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom.
  • Giovannucci EL; Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Goggins MG; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Hartge P; Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Hassan MM; Department of Biology, University of Pisa, Pisa, Italy.
  • Holly EA; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Hoover RN; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Hung RJ; Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology (ICO), Barcelona, Spain.
  • Kurtz RC; Yale Cancer Center, New Haven, Connecticut.
  • Lee IM; Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Malats N; Smilow Cancer Hospital, New Haven, Connecticut.
  • Milne RL; Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ng K; Boston Veteran Affairs Healthcare System, Boston, Massachusetts.
  • Oberg AL; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Panico S; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Peters U; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Porta M; Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Rabe KG; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Cancer Res ; 81(11): 3134-3143, 2021 06 01.
Article in En | MEDLINE | ID: mdl-33574088
ABSTRACT
Germline variation and smoking are independently associated with pancreatic ductal adenocarcinoma (PDAC). We conducted genome-wide smoking interaction analysis of PDAC using genotype data from four previous genome-wide association studies in individuals of European ancestry (7,937 cases and 11,774 controls). Examination of expression quantitative trait loci data from the Genotype-Tissue Expression Project followed by colocalization analysis was conducted to determine whether there was support for common SNP(s) underlying the observed associations. Statistical tests were two sided and P < 5 × 10-8 was considered statistically significant. Genome-wide significant evidence of qualitative interaction was identified on chr2q21.3 in intron 5 of the transmembrane protein 163 (TMEM163) and upstream of the cyclin T2 (CCNT2). The most significant SNP using the Empirical Bayes method, in this region that included 45 significantly associated SNPs, was rs1818613 [per allele OR in never smokers 0.87, 95% confidence interval (CI), 0.82-0.93; former smokers 1.00, 95% CI, 0.91-1.07; current smokers 1.25, 95% CI 1.12-1.40, P interaction = 3.08 × 10-9). Examination of the Genotype-Tissue Expression Project data demonstrated an expression quantitative trait locus in this region for TMEM163 and CCNT2 in several tissue types. Colocalization analysis supported a shared SNP, rs842357, in high linkage disequilibrium with rs1818613 (r 2 = 0. 94) driving both the observed interaction and the expression quantitative trait loci signals. Future studies are needed to confirm and understand the differential biologic mechanisms by smoking status that contribute to our PDAC findings.

SIGNIFICANCE:

This large genome-wide interaction study identifies a susceptibility locus on 2q21.3 that significantly modified PDAC risk by smoking status, providing insight into smoking-associated PDAC, with implications for prevention.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Chromosomes, Human, Pair 2 / Smoking / Genetic Predisposition to Disease / Polymorphism, Single Nucleotide / Carcinoma, Pancreatic Ductal / Quantitative Trait Loci Type of study: Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Res Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Chromosomes, Human, Pair 2 / Smoking / Genetic Predisposition to Disease / Polymorphism, Single Nucleotide / Carcinoma, Pancreatic Ductal / Quantitative Trait Loci Type of study: Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Res Year: 2021 Document type: Article